NovAliX and Servier Collaborate in Early Discovery Research ProgramNovAlix

News

NovAliX and Servier Collaborate in Early Discovery Research Program
09 Oct 2012

NovAliX has announced today that it has entered into drug discovery collaboration with the pharmaceutical company Servier.

Under the terms of this agreement Graffinity, a NovAliX subsidiary, will be responsible for the discovery of specific small molecule lead candidates for a novel exploratory target chosen by Servier. NovAliX will identify hits using its Graffinity fragment-based screening technology that combines chemical micro-arrays with a proprietary SPR-imaging method for the detection of compound protein interactions. NovAliX will receive technology access fees and research funding from Servier.

"We look forward to utilizing NovAliX's strong capabilities in biophysics and lead generation methodologies for this novel discovery program" said Bernard Marchand, PhD, Head of Servier Discovery Research.

Stephan Jenn, President of NovAliX, said "This drug discovery collaboration with a leading global pharmaceutical confirms the quality of our technologies and science, and underlines the value of our platform as an important tool to deliver valuable lead candidates."

Request Info

Company website

Tags: surface plasmon resonance